{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T23:57:45Z","timestamp":1694995065153},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":430,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Apheresis"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jca.21343","type":"journal-article","created":{"date-parts":[[2014,6,28]],"date-time":"2014-06-28T04:43:47Z","timestamp":1403930627000},"page":"28-31","source":"Crossref","is-referenced-by-count":2,"title":["Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000\/\u00b5l"],"prefix":"10.1002","volume":"30","author":[{"given":"Weihong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Shenzhen Second People's Hospital; The First Affiliated Hospital of Shenzhen University; Shenzhen Guangdong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Division of Hematologic Malignancies and Cellular Therapy; Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Drago","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Division of Hematologic Malignancies and Cellular Therapy; Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,28]]},"reference":[{"key":"10.1002\/jca.21343-BIB0001|jca21343-cit-0001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/SCT.2005.n.023","article-title":"Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia","volume":"3","author":"Crawford","year":"2005","journal-title":"Support Cancer Ther"},{"key":"10.1002\/jca.21343-BIB0002|jca21343-cit-0002","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/07357909809115775","article-title":"A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression","volume":"16","author":"Beveridge","year":"1998","journal-title":"Cancer Invest"},{"key":"10.1002\/jca.21343-BIB0003|jca21343-cit-0003","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-03-0675","article-title":"Current trends in hematopoietic stem cell transplantation in Europe","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"key":"10.1002\/jca.21343-BIB0004|jca21343-cit-0004","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.bmt.1705104","article-title":"Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/jca.21343-BIB0005|jca21343-cit-0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/asheducation-2005.1.469","article-title":"Evaluation of hematopoietic stem cell donors","author":"Horowitz","year":"2005","journal-title":"Hematology Am Soc of Hematol Educ Program Book"},{"key":"10.1002\/jca.21343-BIB0006|jca21343-cit-0006","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bmt.1702875","article-title":"Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases","volume":"27","author":"Anderlini","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/jca.21343-BIB0007|jca21343-cit-0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.transci.2004.10.007","article-title":"Mobilization and collection of peripheral blood progenitor cells for transplantation","volume":"32","author":"Reddy","year":"2005","journal-title":"Transfus Apher Sci"},{"key":"10.1002\/jca.21343-BIB0008|jca21343-cit-0008","first-page":"279","article-title":"Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen","volume":"18","author":"Waller","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/jca.21343-BIB0009|jca21343-cit-0009","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1537-2995.1996.36796323057.x","article-title":"Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedure","volume":"36","author":"Anderlini","year":"1996","journal-title":"Transfusion"},{"key":"10.1002\/jca.21343-BIB0010|jca21343-cit-0010","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.bmt.1702038","article-title":"Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors","volume":"24","author":"Murata","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/jca.21343-BIB0011|jca21343-cit-0011","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.bmt.1704743","article-title":"Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience","volume":"35","author":"Pulsipher","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/jca.21343-BIB0012|jca21343-cit-0012","first-page":"237","article-title":"Collection of hematopoietic progenitor cells from healthy donors","volume":"63","author":"Bojani\u0107","year":"2009","journal-title":"Acta Med Croatica"},{"key":"10.1002\/jca.21343-BIB0013|jca21343-cit-0013","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2141.2006.06312.x","article-title":"Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project","volume":"135","author":"Bennett","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1002\/jca.21343-BIB0014|jca21343-cit-0014","first-page":"113:3604","article-title":"Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"key":"10.1002\/jca.21343-BIB0015|jca21343-cit-0015","first-page":"903","article-title":"Allogeneic blood stem cell transplantation: considerations for donors","volume":"90","author":"Anderlini","year":"1997","journal-title":"Blood"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jca.21343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T17:38:21Z","timestamp":1625506701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21343"}},"subtitle":["Safety of Growth Factor Administration"],"short-title":[],"issued":{"date-parts":[[2014,6,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jca.21343","relation":{},"ISSN":["0733-2459"],"issn-type":[{"value":"0733-2459","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6,28]]}}}